WebNews
Please enter a web search for web results.
NewsWeb
Giredestrant Shows Consistent IDFS Benefit Regardless of Menopausal Status in Early Breast Cancer
1+ hour, 42+ min ago (333+ words) Giredestrant demonstrates invasive disease-free survival (IDFS) benefit regardless of menopausal status among patients with estrogen receptor-positive/HER2-negative (ER+/HER2-) early breast cancer (e BC), according to findings from the phase 3 lid ERA BC trial to be presented at the 2026 American Society…...
OPTIMA Phase III: Gene Expression Test Helps Identify Patients Who May Avoid Chemotherapy
1+ day, 14+ hour ago (226+ words) The non-inferiority (NI) randomized controlled OPTIMA trial (Optimal Personalized Treatment of early breast cancer using Multi-parameter Analysis) evaluated whether a Prosigna gene expression test-directed approach could maintain comparable 5-year invasive breast cancer-free survival (IBCFS) outcomes relative to standard treatment. Results…...
Expert Exchange: ESR1 Mutations in ER+/HER2- Metastatic Breast Cancer
2+ week, 5+ day ago (171+ words) Docwire News Expert Exchange: ESR1 Mutations in ER+/HER2- Metastatic Breast Cancer Expert Roundtable: Managing ESR1 Mutated ER+/HER2" Metastatic Breast Cancer This fiveepisode expert roundtable brings together leading breast oncologists for a candid, practicefocused discussion on managing ESR1mutated ERpositive/HER2negative metastatic breast cancer. Across the…...
SATEEN: Limited Activity With Sacituzumab Govitecan Plus Trastuzumab After Prior T-DXd in
3+ week, 1+ day ago (248+ words) Results from the phase II SATEEN trial presented this week at the 2026 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany, suggest that sacituzumab govitecan (SG) plus trastuzumab has limited activity in patients with HER2-positive metastatic…...
Can Dynamic Biomarkers Change Treatment Decisions?
1+ mon, 3+ week ago (476+ words) Docwire News Can Dynamic Biomarkers Change Treatment Decisions? Margaret Gatti'Mays, MD, MPH, examines whether dynamic biomarkers such as circulating tumor DNA (ct DNA) are ready to meaningfully change treatment decisions in breast cancer care. She outlines key practical challenges clinicians…...
Why ct DNA Is Emerging as the Most Powerful Biomarker
2+ mon, 6+ day ago (132+ words) Dr. Margaret Gatti'Mays highlights circulating tumor DNA (ct DNA) as the leading dynamic biomarker in breast cancer. She explains how ct DNA helps detect minimal residual disease, track mutation development, and monitor treatment response in early and metastatic settings. The…...
ASCENT-04/KEYNOTE-D19: What a 3. 4-Month PFS Gain Means for First-Line PD-(L)1 Positive m TNBC
3+ mon, 2+ week ago (1045+ words) Docwire News ASCENT-04/KEYNOTE-D19: What a 3. 4-Month PFS Gain Means for First-Line PD-(L)1 Positive m TNBC In this interview, Rebecca Shatsky, MD, discusses the significant clinical impact of the ASCENT04/KEYNOTED19 trial for patients with PD(L)1positive metastatic triple-negative breast cancer. She explains…...